+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Determination of Etelcalcetide Biotransformation and Hemodialysis Kinetics to Guide the Timing of Its Dosing



Determination of Etelcalcetide Biotransformation and Hemodialysis Kinetics to Guide the Timing of Its Dosing



Kidney International Reports 1(1): 24-33



Etelcalcetide, a novel calcimimetic agonist of the calcium-sensing receptor for treatment of secondary hyperparathyroidism in chronic kidney disease patients on hemodialysis, is a d-amino acid linear heptapeptide with a d-cysteine that is linked to an l-cysteine by a disulfide bond. In addition to binding to the calcium-sensing receptor, etelcalcetide is biotransformed by disulfide exchange in whole blood to predominantly form a covalent serum albumin peptide conjugate (SAPC). Key factors anticipated to affect the pharmacokinetics and disposition of etelcalcetide in chronic kidney disease patients on hemodialysis are the drug's intrinsic dialytic properties and biotransformation kinetics. These factors were investigated using in vitro methods, and the findings were modeled to derive corresponding kinetic rate constants. Biotransformation was reversible after incubation of etelcalcetide or SAPC in human whole blood. The rate of SAPC formation from etelcalcetide was 18-fold faster than the reverse process. Clearance of etelcalcetide by hemodialysis was rapid in the absence of blood and when hemodialysis was initiated immediately after addition of etelcalcetide to blood. Preincubation of etelcalcetide in blood for 3 hours before hemodialysis resulted in formation of SAPC and decreased its clearance due to the slow rate of etelcalcetide formation from SAPC. Etelcalcetide hemodialysis clearance was >16-fold faster than its biotransformation. These results indicate that etelcalcetide should be administered after hemodialysis to avoid elimination of a significant fraction of the dose.

(PDF emailed within 0-6 h: $19.90)

Accession: 057793015

Download citation: RISBibTeXText

PMID: 29318205

DOI: 10.1016/j.ekir.2016.04.002


Related references

Pharmacokinetics, Biotransformation, and Excretion of [ 14 C]Etelcalcetide (AMG 416) Following a Single Microtracer Intravenous Dose in Patients with Chronic Kidney Disease on Hemodialysis. Clinical Pharmacokinetics 56(2): 179-192, 2016

Dosing of Etelcalcetide and Cinacalcet for Secondary Hyperparathyroidism. JAMA 317(20): 2132, 2017

Volume of urea cleared as a therapy dosing guide for more frequent hemodialysis. Hemodialysis International. International Symposium on Home Hemodialysis 2018, 2018

Managing hyperparathyroidism in hemodialysis: role of etelcalcetide. International Journal of Nephrology and Renovascular Disease 11: 69-80, 2018

A light in the control of secondary hyperparathyroidism. Etelcalcetide IV in hemodialysis. Nefrologia 38(6): 677-678, 2018

Etelcalcetide: injectable calcimimetic for the treatment of secondary hyperparathyroidism in hemodialysis-dependent patients. Drugs of Today 53(9): 489-500, 2018

Etelcalcetide (Parsabiv) for Secondary Hyperparathyroidism in Adults With Chronic Kidney Disease on Hemodialysis. P and T 43(7): 396-399, 2018

Early viral kinetics: a novel guide for optimal dosing frequency of pegylated interferon-╬▒-2a in HIV/HCV-coinfected patients. Expert Review of Anti-Infective Therapy 9(10): 859-862, 2011

Theoretical overview of clinical and pharmacological aspects of the use of etelcalcetide in diabetic patients undergoing hemodialysis. Drug Design, Development and Therapy 12: 901-909, 2018

A Single- and Multiple-Dose, Multicenter Study of Etelcalcetide in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism. Kidney International Reports 2(4): 634-644, 2017

Long-term effects of etelcalcetide as intravenous calcimimetic therapy in hemodialysis patients with secondary hyperparathyroidism. Clinical and Experimental Nephrology 22(2): 426-436, 2017

Determination of the optimum timing for pharmacokinetic monitoring of once daily aminoglycoside dosing. Intensive Care Medicine 20(3): 243-244, 1994

Population Pharmacokinetics and Pharmacodynamics of the Calcimimetic Etelcalcetide in Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis. Cpt: Pharmacometrics and Systems Pharmacology 5(9): 484-494, 2017

Role of etelcalcetide in the management of secondary hyperparathyroidism in hemodialysis patients: a review on current data and place in therapy. Drug Design, Development and Therapy 12: 1589-1598, 2018

Drug disposition model of radiolabeled etelcalcetide in patients with chronic kidney disease and secondary hyperparathyroidism on hemodialysis. Journal of Pharmacokinetics and Pharmacodynamics 44(1): 43-53, 2017